June 11, 2020
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: | Paul Fischer | ||
|
| ||
Re: | Axovant Gene Therapies Ltd. | ||
| Registration Statement on Form S-3 | ||
| File No. 333-235889 | ||
|
| ||
| Acceleration Request | ||
|
| Requested Date: | Monday, June 15, 2020 |
|
| Requested Time: | 4:00 P.M. Eastern Standard Time |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-235889) (the “Registration Statement”) to become effective on June 15, 2020, at 4:00 p.m. Eastern Standard Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with John McKenna of Cooley LLP, counsel to the Registrant, at (650) 843-5059, or in his absence, Milson Yu at (650) 843-5296.
[Signature page follows]
|
| Very truly yours, | ||
|
|
| ||
|
| Axovant Gene Therapies Ltd. | ||
|
|
| ||
|
|
| ||
|
| By: | /s/ David Nassif | |
|
|
| David Nassif | |
|
|
| Principal Financial Officer | |
|
|
|
| |
cc: | Pavan Cheruvu, Axovant Gene Therapies Ltd. |
|
| |
| John McKenna, Cooley LLP |
|
| |
| Milson Yu, Cooley LLP |
|
| |
